High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer.
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer.
复制标题
高剂量速率近距离放射治疗单药治疗与图像引导的强度调节放射疗法对局部前列腺癌患者的螺旋疗法进行了放射疗法。
DOI：
10.3390/cancers10090322
复制
发表时间：
2018-09-10
期刊：
影响因子：
5.2
通讯作者：
Ogawa K
中科院分区：
文献类型：
--
作者：
Yamazaki H;Masui K;Suzuki G;Nakamura S;Shimizu D;Nishikawa T;Okabe H;Yoshida K;Kotsuma T;Tanaka E;Otani K;Yoshioka Y;Ogawa K
本文的目的是比较高剂量率组织间近距离放射治疗（HDR-BT）单一疗法和图像引导调强放疗（IG-IMRT）治疗局限性前列腺癌的结局。我们检查了353例HDR-BT和270例IG-IMRT患者。为了减少背景选择偏倚，我们使用了具有倾向评分的逆概率治疗加权（IPTW）方法。精算五年生化无失败生存率分别为92.9%和96.7%（p = 0.1847; IPTW中p = 0.077）分别用于HDR-BT和IG-IMRT;分别为100%和95.8%（p = 0.286）对于低风险组，95.6%和92%（p = 0.42）中危组分别为90.4%和84.9%（p = 0.1059; IPTW中p = 0.04），极高危组为87.1%和89.2%（p = 0.3816）。在评估5年时≥ 2级毒性的累积发生率（不良事件通用术语标准第4.0版）时，HDR-BT单药治疗显示生殖泌尿系统毒性（11.9%）高于IG-IMRT（3.3%）（p < 0.0001）。HDR-BT（2.3%）和IG-IMRT（5.5%）的胃肠道毒性相当（p = 0.063）。两种方式均未检测到4级或5级毒性。HDR-BT的泌尿生殖系统毒性高于IG-IMRT。HDR-BT和IG-IMRT在低、中和极高风险组中显示出相同的结局。对于高危患者，HDR-BT显示出与IG-IMRT相比改善前列腺特异性抗原（PSA）控制率的潜力。
The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used the method of inverse probability treatment weighting (IPTW) with propensity scores. The actuarial five-year biochemical failure-free survival rates were 92.9% and 96.7% (p = 0.1847; p = 0.077 in IPTW) for HDR-BT and IG-IMRT, respectively; they were 100% and 95.8% (p = 0.286) for the low-risk group, 95.6% and 92% (p = 0.42) for the intermediate-risk group, 90.4% and 84.9% (p = 0.1059; p = 0.04 in IPTW) for the high-risk group, and 87.1% and 89.2% (p = 0.3816) for the very-high-risk group. In the assessment of accumulated incidences of grade ≥ 2 toxicity (Common Terminology Criteria for Adverse Events version 4.0) at five years, HDR-BT monotherapy showed higher genitourinary toxicity (11.9%) than IG-IMRT (3.3%) (p < 0.0001). The gastrointestinal toxicity was equivalent for HDR-BT (2.3%) and IG-IMRT (5.5%) (p = 0.063). No Grade 4 or 5 toxicity was detected in either modality. HDR-BT showed higher genitourinary toxicity than IG-IMRT. HDR-BT and IG-IMRT showed equivalent outcomes in low-, intermediate-, and very-high-risk groups. For high-risk patients, HDR-BT showed potential to improve prostate-specific antigen (PSA) control rate compared to IG-IMRT.
登录
查看更多内容
DOI：
10.1016/s0360-3016(00)00687-8
发表时间：
2000-10-01
影响因子：
7
作者：
Yoshioka, Y;Nose, T;Inoue, T
通讯作者：
Inoue, T
影响因子：
2
作者：
Yamazaki H;Nakamura S;Nishimura T;Yoshida K;Yoshioka Y;Koizumi M;Ogawa K
通讯作者：
Ogawa K
影响因子：
2
作者：
Sasaki, Naomi;Yamazaki, Hideya;Yoshida, Ken
通讯作者：
Yoshida, Ken
DOI：
10.1016/j.ijrobp.2011.11.047
发表时间：
2012-09-01
影响因子：
7
作者：
Zelefsky, Michael J.;Kollmeier, Marisa;Hunt, Margie
通讯作者：
Hunt, Margie
影响因子：
5.7
作者：
Yamazaki, Hideya;Masui, Koji;Ogawa, Kazuhiko
通讯作者：
Ogawa, Kazuhiko